Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    50.0%

    Based on 1 completed trials

    Completion Rate
    50%(1/2)
    Active Trials
    0(0%)
    Results Posted
    200%(2 trials)
    Terminated
    1(33%)

    Phase Distribution

    Phase 2
    2
    67%
    Not Applicable
    1
    33%

    Phase Distribution

    0

    Early Stage

    2

    Mid Stage

    0

    Late Stage

    Phase Distribution3 total trials
    Phase 2Efficacy & side effects
    2(66.7%)
    N/ANon-phased studies
    1(33.3%)

    Highest Phase Reached

    Phase 2

    Trial Status & Enrollment

    Completion Rate

    50.0%

    1 of 2 finished

    Non-Completion Rate

    50.0%

    1 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Completed(1)
    Terminated(1)
    Other(1)

    Detailed Status

    Completed1
    Terminated1
    unknown1

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    0
    Success Rate
    50.0%
    Most Advanced
    Phase 2

    Trials by Phase

    Phase 22 (66.7%)
    N/A1 (33.3%)

    Trials by Status

    completed133%
    terminated133%
    unknown133%

    Recent Activity

    0 active trials
    Showing 3 of 3
    completedphase_2

    Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia

    NCT01143389
    terminatednot_applicable

    Cross Linking for Treatment of Corneal Infection

    NCT00912509
    unknownphase_2

    UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

    NCT01325298

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT01143389Phase 2

    Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia

    Completed
    NCT00912509Not Applicable

    Cross Linking for Treatment of Corneal Infection

    Terminated
    NCT01325298Phase 2

    UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

    Unknown

    All 3 trials loaded

    Drug Details

    Intervention Type
    Device
    Total Trials
    3